United Therapeutics Other Non-cash Income and Expense decreased by 195.2% to -$32.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 680.5%, from -$4.10M to -$32.00M. Over 4 years (FY 2021 to FY 2025), Other Non-cash Income and Expense shows an upward trend with a -26.1% CAGR.
orcl_other_noncash_income_expense| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$5.50M | -$31.00M | -$37.90M | $12.20M | -$46.80M | -$10.00M | -$7.90M | -$5.80M | $3.90M | $1.80M | $5.00M | $10.50M | $5.50M | $5.70M | $2.60M | -$4.10M | -$9.90M | $100.00K | $33.60M | -$32.00M |
| QoQ Change | — | -463.6% | -22.3% | +132.2% | -483.6% | +78.6% | +21.0% | +26.6% | +167.2% | -53.8% | +177.8% | +110.0% | -47.6% | +3.6% | -54.4% | -257.7% | -141.5% | +101.0% | >999% | -195.2% |
| YoY Change | — | — | — | — | -750.9% | +67.7% | +79.2% | -147.5% | +108.3% | +118.0% | +163.3% | +281.0% | +41.0% | +216.7% | -48.0% | -139.0% | -280.0% | -98.2% | >999% | -680.5% |